• Technology
    • Resources
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Stock Information
      • Stock Quote & Chart
    • Corporate Governance
      • Documents & Charters
      • Leadership
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
    • IR Resources
      • FAQs
      • Email Alerts
      • Contact IR
  • Blog
  • Contact
Nautilus Biotechnology
  • Technology
    • Resources
  • Company
  • Collaborate
  • Careers
  • Investors
    • News & Events
    • Stock Information
    • Corporate Governance
    • Financial Information
    • IR Resources
  • Blog
  • Contact

Proteomics could unlock how tau protein and Alzheimer’s are linked

November 8, 2022
Greg Kapp
LinkedIn

Photo of Nautilus' Associate Director of Applications Development presenting a poster at the Alzheimer's Association International Conference (AAIC)

 

Despite concerted efforts to understand Alzheimer’s disease and the many hypothesized causes of Alzheimer’s disease over the past decades, the disease remains a challenge for researchers and a devastating diagnosis for families. However, the growing field of proteomics could soon offer new answers. 

 

On the surface, we watch as the animate light in someone’s eyes slowly dims and they try to grasp at memories that are no longer there. In their brain, a slow buildup of proteins forms beta amyloid plaques and tau tangles, both of which seem linked with Alzheimer’s disease  progression and decreased neural function. Understanding how tau proteins and Alzheimer’s are linked will help us better understand and treat not only Alzheimer’s, but also many other diseases. To get there, we need a better understanding of specific proteins like tau and the whole proteome, the collection of all the proteins inside cells and tissues. The growing field of proteomics, and new technologies like the cutting-edge Nautilus Proteome Analysis Platform, could be the solution. 

 

Tau protein an Alzheimer’s disease

Alzheimer’s disease is usually linked with dementia or cognitive decline, which can be hard to differentiate from the natural consequences of aging. One strategy for early diagnosis of Alzheimer’s disease (and then treatment) is to identify specific biomarker proteins, like beta amyloid and tau proteins, that may be involved or change in the early stages of the disease. Some current theories hold that these proteins could be misfolding and aggregating, collecting in the brain, disrupting normal cellular function, and leading to cognitive declines. 

 

There’s still debate about the role these different proteins play in Alzheimer’s. However, it’s clear that more information on biomarker proteins that either distinguish Alzheimer’s disease or differentiate the various stages of the disease would improve patient care, diagnosis, and clinical feedback on new therapies. 

 

Identifying the early stages of Alzheimer’s disease is particularly important for improving patient lives because, if researchers can develop therapeutics that address these early stages, we may slow or stop progression to wider brain dysfunction. Identifying specific variations of the tau protein, called proteoforms, may be the key to developing improved biomarkers for Alzheimer’s early stages. 

 

To achieve this, we need to be able to more thoroughly characterize the tau protein. For that, it’s essential to have new tools that enable high-throughput protein quantification and identification while also providing more detailed analysis of specific proteins and proteoforms. This deeper level of investigation, into both the whole proteome and individual proteins and proteoforms, will improve our understanding of Alzheimer’s biomarkers and biology. That requires groundbreaking new approaches in proteomics technology, much like what we’ve seen in the field of genomics. We hope the Nautilus platform will provide this quantum leap in proteomic analysis.

 

Using the Nautilus Proteome Analysis Platform to probe the tau protein

We’ve been studying the tau protein and its proteoforms using the Nautilus Proteome Analysis Platform in collaboration with Genentech. We shared some of our preliminary findings during a recent poster presentation at the Alzheimer’s Association International Conference (AAIC), the world’s largest dementia research forum. Our data shows how we can use commercial antibodies (existing tools) coupled with the powerful single-molecule analysis capabilities of the Nautilus platform to learn more about the proteoforms associated with Alzheimer’s disease. In this case, we used antibodies targeting tau protein and tau phospho-proteins to explore the different tau proteoforms that might exist in a sample.  

 

The tau protein can be highly modified in our bodies — it is one of the human proteins with the most identified post-translational modifications. This makes tau protein analysis incredibly challenging because there are hundreds to thousands of possible tau proteoforms. The tau proteoform distribution (the complete set of existing proteoforms) changes over time in healthy patients, over the course of disease, between various parts of the body, and possibly over the course of treatment. This incredible complexity makes understanding tau proteoforms and their biological relevance to diseases like Alzheimer’s difficult. Nonetheless, it highlights how much there is to learn about tau and underlines the need for technologies like the Nautilus platform that enable us to look deeper into tau proteoforms and how they can cause Alzheimer’s and other diseases.

 

Alzheimer’s disease proteomics

Our goal is to demonstrate that a new approach to protein and proteoform analysis can improve human health. The collaboration with Genentech is focused on tau and Alzheimer’s disease, but there are other proteins, like beta amyloid, hypothesized to be involved in Alzheimer’s disease as well. The Nautilus platform is built to enable deep protein analysis of tau and any other protein that could be a key Alzheimer’s biomarker or therapeutic target. Nautilus’ overall goal is to enable scientists and researchers to dig deeper into protein analysis of specific proteins, proteoforms, and whole proteomes. Having access to this kind of deep proteomic analysis will revolutionize our understanding of the complexities of human proteins and complement other technologies to shape the next 10 years of advancements in how we understand, diagnose, and treat disease.   

 

While our current collaboration with Genentech is focused on Tau and Alzheimer’s disease, there are many other proteins hypothesized to be involved in the onset and progression of Alzheimer’s disease. The Nautilus platform is built to enable deep analysis of Tau and of any protein that could be a key biomarker or therapeutic target. Our overall goal is to enable deeper protein analysis of specific proteins and proteoforms, and of whole proteomes. Having access to this kind of deep analysis will revolutionize how we understand the complexities of human proteins and complement other technologies to shape the next 10 years of advancements in how we visualize, measure, and treat disease.

Browse by topic

  • Nautilus in the News
  • Events
  • Research and collaborations
  • Nautilus and our Platform
  • Proteomics
  • Life at Nautilus
  • Industry Interviews
SUBSCRIBE
Back To Blog

Nautilus Biotechnology

 

Corporate Headquarters
2701 Eastlake Avenue East
Seattle, WA 98102

 

Research Headquarters
835 Industrial Road, Suite 200
San Carlos, CA 94070

 

     

+1 (206) 333-2001

© 2023 Nautilus Biotechnology Inc.
All Rights Reserved.

Privacy Policy | Terms of Use

We use cookies in order to continually improve your experience on our website. By clicking “Accept cookies” or clicking on any content on our site, you are consenting to our use of cookies as described in our Privacy Policy. You can opt-out if you wish. Accept Reject All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT